|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1991-12-6
|
|
pubmed:abstractText |
The trial entered 66 patients with recurrent erysipelas treated conventionally with addition of either immunostimulator bemitil (0.25-0.5 g/day orally for 5-7 days) or placebo. The bemitil group was free of intoxication symptoms and local manifestations, discharged from hospital sooner than the controls. Therapeutic efficacy of bemitil is due to its promotion of mononuclear phagocytes function which acts as an essential mechanism of antibacterial defence activation in patients with recurrent erysipelas.
|
|
pubmed:language |
rus
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0023-2149
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
89-90
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1942990-Adjuvants, Immunologic,
pubmed-meshheading:1942990-Adult,
pubmed-meshheading:1942990-Benzimidazoles,
pubmed-meshheading:1942990-Combined Modality Therapy,
pubmed-meshheading:1942990-Drug Administration Schedule,
pubmed-meshheading:1942990-Erysipelas,
pubmed-meshheading:1942990-Humans,
pubmed-meshheading:1942990-Immune Tolerance,
pubmed-meshheading:1942990-Middle Aged,
pubmed-meshheading:1942990-Placebos,
pubmed-meshheading:1942990-Recurrence,
pubmed-meshheading:1942990-Ultraviolet Therapy
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
[Effectiveness of bemitil in recurrent erysipelas].
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Controlled Clinical Trial
|
